ストックスクリーナーアプリを入手
131.78
2.07%
2.67
前日終値:
$129.11
開ける：
$132.48
24時間の取引高:
3.41M
Relative Volume:
1.55
時価総額：
$17.47B
収益：
$1.08B
当期純損益:
$-433.19M
株価収益率:
-38.75
EPS:
-3.4004
ネットキャッシュフロー:
$-225.09M
1週間 パフォーマンス:
+0.67%
1か月 パフォーマンス:
+37.76%
6か月 パフォーマンス:
+35.72%
1年 パフォーマンス:
+160.59%
1日の値動き範囲:
$130.19
$134.00
1週間の範囲:
$125.00
$135.00
52週間の値動き範囲:
$40.35
$135.00
Guardant Health Inc Stock (GH) Company Profile
Compare GH vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
131.78 | 17.47B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
464.61 | 172.66B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.17 | 125.40B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.09 | 44.34B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
127.06 | 35.89B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
355.44 | 34.90B | 3.77B | 449.25M | 240.68M | 7.8556 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-20 | 繰り返されました | Canaccord Genuity | Buy |
| 2026-02-17 | 開始されました | Robert W. Baird | Outperform |
| 2026-01-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-12-02 | 再開されました | Morgan Stanley | Overweight |
| 2025-09-25 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | 再開されました | Wells Fargo | Overweight |
| 2025-04-10 | 開始されました | Mizuho | Outperform |
| 2025-01-23 | 開始されました | Barclays | Overweight |
| 2024-06-28 | アップグレード | Guggenheim | Neutral → Buy |
| 2024-06-03 | 再開されました | Jefferies | Buy |
| 2024-04-24 | 再開されました | Craig Hallum | Buy |
| 2023-12-14 | 開始されました | Guggenheim | Neutral |
| 2023-12-13 | 開始されました | Wolfe Research | Peer Perform |
| 2023-11-13 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 開始されました | Bernstein | Outperform |
| 2023-09-27 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 再開されました | JP Morgan | Overweight |
| 2023-05-26 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-05 | 開始されました | UBS | Buy |
| 2023-03-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2023-01-05 | 開始されました | Scotiabank | Sector Outperform |
| 2022-11-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 開始されました | Craig Hallum | Buy |
| 2022-10-06 | 開始されました | Stephens | Overweight |
| 2022-08-25 | 開始されました | Credit Suisse | Outperform |
| 2022-06-03 | 開始されました | Piper Sandler | Overweight |
| 2022-04-28 | 再開されました | BTIG Research | Buy |
| 2022-02-24 | 繰り返されました | Canaccord Genuity | Buy |
| 2022-02-24 | 繰り返されました | Citigroup | Buy |
| 2022-02-24 | 繰り返されました | Cowen | Outperform |
| 2022-02-24 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-24 | 繰り返されました | SVB Leerink | Outperform |
| 2022-02-24 | 繰り返されました | Stifel | Buy |
| 2022-02-24 | 繰り返されました | Wells Fargo | Overweight |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-06-15 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-03 | 開始されました | Goldman | Buy |
| 2021-05-25 | 開始されました | Wells Fargo | Overweight |
| 2021-01-11 | 開始されました | Stifel | Buy |
| 2020-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2020-06-12 | 開始されました | BTIG Research | Buy |
| 2020-02-21 | 開始されました | Guggenheim | Buy |
| 2020-01-07 | 開始されました | Citigroup | Buy |
| 2019-08-07 | 繰り返されました | Canaccord Genuity | Buy |
| 2019-04-16 | 開始されました | Canaccord Genuity | Buy |
| 2019-04-10 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 繰り返されました | BofA/Merrill | Neutral |
| 2018-10-29 | 開始されました | BofA/Merrill | Neutral |
| 2018-10-29 | 開始されました | JP Morgan | Overweight |
| 2018-10-29 | 開始されました | William Blair | Outperform |
すべてを表示
Guardant Health Inc (GH) 最新ニュース
Guardant rated new outperform at RBC on catalysts, growth prospects - MSN
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Guardant Health Inc (GH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Guardant Health Inc (GH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Executive pay vote fails as Guardant Health (NASDAQ: GH) investors back auditor - Stock Titan
Guardant Health (NASDAQ: GH) CIO reports RSU vesting and tax-withheld shares - Stock Titan
Guardant Loses Bid to Undo $83 Million DNA-Tech Patent Verdict - Bloomberg Law News
Guardant Health Inc (GH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Guardant Health Inc (GH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Guardant Health director Tariq Musa sells $15,102 in shares - Investing.com
Guardant Health (GH) director logs RSU vesting and sale of 116 shares - Stock Titan
Guardant Health (GH) CLO nets shares from RSU vesting - Stock Titan
Guardant Health (GH) CCO nets shares after RSU vesting and tax withholding - Stock Titan
Guardant Health (GH) insider Musa Tariq reports 580 shares sold in 2026 - Stock Titan
Guardant Health CIO Kalia sells $445k in stock By Investing.com - Investing.com Canada
Guardant Health CIO Kalia sells $445k in stock - Investing.com UK
[Form 4] Guardant Health, Inc. Insider Trading Activity - Stock Titan
GH (GH) affiliate Kumud Kalia notifies proposed sale of 5,000 shares - Stock Titan
GH (NASDAQ: GH) amendment: affiliate sold 5,000 shares for $652,030 - Stock Titan
Kumud Kalia sells shares; GH (NASDAQ: GH) Form 144 lists dates and proceeds - Stock Titan
The Technical Signals Behind (GH) That Institutions Follow - Stock Traders Daily
Guardant Health Inc. (NASDAQ:GH) Shines as a Top Minervini Trend Template and High Growth Momentum Pick - ChartMill
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout
Top Guardant Health Executive Makes Major Insider Move - TipRanks
Guardant Health CIO Kalia sells $652,030 in company stock By Investing.com - Investing.com Australia
Guardant Health CIO Kalia sells $652,030 in company stock - Investing.com
Insider Sell: Kumud Kalia Sells 5,000 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health Chief Information Officer Sold Shares Worth Over $652K - TradingView
Guardant Health (GH) CIO Kumud Kalia sells 5,000 shares in open market - Stock Titan
Guardant Health (GH) Receives Outperform Rating from RBC Capital Markets - GuruFocus
Guardant Health rated new Outperform at RBC (GH:NASDAQ) - Seeking Alpha
Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says - Moomoo
RBC Capital Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $185 - Moomoo
RBC Capital Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $185 - Moomoo
RBC Capital initiates Guardant Health stock coverage with outperform rating - Investing.com
RBC Capital initiates Guardant Health stock coverage with outperform rating By Investing.com - Investing.com Canada
GH Receives FDA Approval for Guardant360 CDx as Companion Diagno - GuruFocus
Guardant Health wins FDA approval for HER2 lung cancer test By Investing.com - Investing.com Australia
Guardant Health wins FDA approval for HER2 lung cancer test - Investing.com
Guardant Health, Inc. Announces FDA Approval Of Guardant360 CDx As Companion Diagnostic For Boehringer Ingelheim?s HERNEXEOS - marketscreener.com
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS - The Joplin Globe
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health co-CEO Helmy Eltoukhy sells $12.6m in stock By Investing.com - Investing.com South Africa
Guardant Health Insider Sold Shares Worth $12,629,969, According to a Recent SEC Filing - Moomoo
Insider Sell: Michael Bell Sells 2,000 Shares of Guardant Health Inc (GH) - GuruFocus
GH Maintained by Mizuho -- Price Target Raised to $175 - GuruFocus
Guardant Health CFO Michael Bell sells $257,240 in company shares By Investing.com - Investing.com Nigeria
Guardant Health co-CEO Helmy Eltoukhy sells $12.6m in stock - Investing.com India
Guardant Health CFO Michael Bell sells $257,240 in company shares - Investing.com
Guardant Health (NASDAQ: GH) co-CEO’s trust sells 100,000 shares in open market - Stock Titan
Guardant Health (GH) CFO sells 2,000 shares in open-market trade - Stock Titan
Guardant Health Inc (GH) 財務データ
収益
当期純利益
現金流量
EPS
1.40%
1.36%
大文字化:
|
ボリューム (24 時間):